Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABBV, but not buy additional shares or sell existing shares. We have also launched Skyrizi for PSA in rheumatology, where we're seeing strong utilization, which is driving accelerated share growth. The total revenue in 2021 was $56.20 billion with a 31% operating margin. I wrote this article myself, and it expresses my own opinions. As with debt, if approval and revenue targets aren't met, it can quickly result in a loss of faith in the company. This could present more profit potential for drugmakers as well as investors. Join the 500.000+ traders worldwide that chose to trade with Capital.com, Also you can contact us: ABBV-916 is targeting Alzheimer's and it is an anti-amyloid antibody, with a similar mechanism of action ("MoA") to recently approved Leqembi, developed by Biogen (BIIB) / Eisai, and likely soon-to-be approved Donanemab, developed by Eli Lilly. After creating the income statement I prepare the discounted cash flow/EBITDA multiple analysis. The company projects the U.S. toxin market (where Botox is the top product) will decline by mid-single digits. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. All rights reserved. Noting the stellar earnings reported by the firm in the first quarter, Richard A. Gonzalez, chairman and CEO of AbbVie, said: An overview of the companys net revenue in Q1 shows a major portion of revenue came from its immunology portfolio, which brought in $6.14bn. Specifically, they have bought $0.00 in company stock and sold $23,102,528.00 in company stock. Payout ratios above 75% are not desirable because they may not be sustainable. I wrote this article myself, and it expresses my own opinions. Abbvie Inc Stock Forecast, Predictions & Price Target - WallStreetZen The difference between trading assets and CFDs. Is this happening to you frequently? I wrote this article myself, and it expresses my own opinions. Management puts this down to "delayed market recovery for new patients starting therapy in Chronic Lymphocytic Leukemia ("CLL") and increasing competition" and has downgraded its FY22 guidance as a result. Other products such as Mavyret and Creon appear to have many more years of blockbuster sales ahead of them, although it is interesting to note that AbbVie no longer reports revenues from its Women's Health division, and scarcely mentions it. As such, I have decreased my own expectations for 2022 based on simply doubling H1'22 revenues to get a FY22 figure, and downgrading growth expectations to 3% per annum until 2026. Venclexta - a "first-in-class BCL-2 inhibitor for multiple hematological malignancies", according to Gonzalez, is forecast for strong growth, whilst Gonzalez has name checked 3 new drugs he expects to be approved by 2026. On 14 January 2022, the FDA approved Abbvies arthritis treatment drug, Rinvoq (upadacitinib), for the treatment of adults with moderately to severely active ulcerative colitis. I will conclude this analysis by stating that, based on all available information, market headwinds and tailwinds, competitors, and opportunities via its products and pipeline, I still consider AbbVie to be a strong investment opportunity. On average, they expect the company's stock price to reach $161.12 in the next twelve months. Other approved ADC's targeting the c-Met protein, a validated target in NSCLC, include Novartis Tabrecta, which has been pegged for peak sales of ~$1.5bn, which seems a realistic target for Teliso given how large the lung cancer market is - the largest of all oncology markets. We're currently running a sale at my private investing ideas service, Haggerston BioHealth, where members get access to portfolios, market alerts, real-time chat, and more. Aurora Cannabis Stock Forecast for 2023 - 2025 - 2030 Our momentum combined with ramping contributions from new products and new indications will drive accelerating revenue and EPS growth through the rest of the year., ABBV has done very well to add to its impressive gains from the past couple of years. For full year 2022, Abbvie predicted the adjusted diluted EPS guidance range at $14.00 to $14.20 and $13.92 to $14.12. It revealed that patients with moderate to severe Crohns disease receiving Abbvies Rinvoq achieved steroid-free clinical remission in significantly higher numbers than patients receiving a placebo. Earnings for AbbVie are expected to decrease by -0.55% in the coming year, from $11.00 to $10.94 per share. If you have an ad-blocker enabled you may be blocked from proceeding. That was below AbbVie stock analysts' view for $14.16. Although Wallet Investor did not provide targets for 2030, its longer-term Abbvie stock prediction expected the price to hit $300.386 in June 2027. I have no business relationship with any company whose stock is mentioned in this article. Management believes these 2 drugs could one day generate $15bn in peak sales, going a long way to solving the Humira loss of exclusivity ("LOE") problem. But AbbVie is also keen to explore solid tumors, and I am therefore adding an additional $1.5bn of revenues from that source by 2030. See what's happening in the market right now with MarketBeat's real-time news feed. Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing. Drug pricing is another issue - there is bipartisan, and international pressure on US Pharmas to reduce drug pricing, particularly outside of the US. All generate blockbuster <$1bn per annum sales - in Stelara's case >$9bn per annum, and in Enbrel's case, >$4.5bn. I am not receiving compensation for it (other than from Seeking Alpha). As such, forecasting stock prices is more of an art than a science. Disclaimer. 580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Drug development has not traditionally been one of AbbVie's strengths - it has not had to be - but we ought to see the positive results of heavy investment into the oncology pipeline over the next 5-7 years, and by 2030, I believe this division could account for >17% of AbbVie's total revenues. And never invest or trade money you cannot afford to lose. My EPS figure increases slightly between 2022 and 2023, whilst AbbVie has suggested it will be down slightly before beginning to accelerate towards the end of the decade, as revenues correspondingly begin to climb sharply once the worst of the Humira LOE is over. How do I arrive at my share price target? The company has a robust pipeline of new products that are in some stage of clinical trials. Botox accounts for the bulk of the companys Aesthetics portfolio revenue and about 4% of the net as of 2022. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. There are still very few approved therapies, although that could change with Crispr Therapeutics (CRSP) / Vertex (VRTX) Sickle Cell Disease therapy leading the charge in 2023. Venclexta continues to pick up momentum with sales up 16% to >$500m in Q2'22, and I forecast the drug to exceed $3.2bn in revenues by the end of the decade. The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". The shining star in the aesthetics business is Botox, which increased sales by 45% year over year to $477 million in the first quarter of 2021. This included an unfavourable impact of $0.08 a share related to acquired in-process research and development (IPR&D) and milestones expenses incurred during the March quarter. Bringing RGX314 would be a coup for AbbVie although I am forecasting for only $2bn in peak revenues in 2030 as a hedge against the risk that this candidate does not make it to market on safety grounds. AbbVie CEO Gonzalez told the audience at the JPM Healthcare conference that: We now have a little over 90% access for next year for Humira at parity. z o.o., AbbVie Productos Farmacuticos Limitada, AbbVie Products LLC, AbbVie Promoo L.da, AbbVie Pte. Having dived into the numbers however and looked ahead to 2030 through the eyes and guidance of management, my conclusion is that investors can probably buy AbbVie stock at current price with reasonably high hopes of making a decent ROI - perhaps 15 - 20% in the next 12 - 18 months, whilst also benefiting from a generous dividend. The fact that my own forecasts are less ambitious than management's reflects the fact I have not introduced new products into my forecasts, and it will be interesting to see how management performs on that front as AbbVie has not really had to have a string pipeline while Humira has delivered such dominance in the auto-immune markets. The company is a member of the Fortune 100 and one of the Fortune 100s Best Companies To Work For. All Rights Reserved. Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. Allergan was a troubled company in many ways, but there is no doubting the strength of its products and pipeline. This figure could eventually end up substantially larger - according to Gonzalez: We've begun to see some very exciting data from several solid tumor programs, including our anti-GARP antibody ABBV-151, and our PTK7 ADC, ABBV-647. Nineteen analysts predict that AbbVie's share price will increase in the coming year, reaching $165.00. Management are very optimistic on Vraylar, with Gonzalez describing it as "now the only antipsychotic that is a dopamine and serotonin partial agonist approved for the treatment of the most common forms of depression, Bipolar 1 and MDD" and targeting >$5bn peak sales. I'm on twitter @edmundingham. On average, analysts forecast that ABBV's EPS will be $11.80 for 2023, with the lowest EPS . 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Skyrizi has also been approved to treat Crohn's Disease, an added bonus and another multi-billion dollar market. AbbVie Inc. (ABBV) Stock Forecast & Price Targets - Stock Analysis Among the more notable are ImmuVen, Pharamcyclics and Allergan plc. In-depth profiles and analysis for 20,000 public companies. Furthermore, it seems sales of Lupron and Synthroid have joined the "All Other" section, which has generated $2.2bn of revenues in the first half of 2022, versus $1.5bn in the first half of 2021. Abbvie stock price has put up an impressive performance in 2022. The company's lead asset - all-time best selling immunology drug Humira - finally loses patent protection this year and sales will enter a period of terminal decline. Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. Please. AbbVie sees strong 2022 earnings as Botox, Skyrizi power profit beat What other stocks do shareholders of AbbVie own? The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. In the next year, analysts predict that Revenue will reach C$253.83M - an increase of 3.50%. In 2022, Humira revenues will likely reach $21bn, which will see the drug overtake cholesterol-lowering Lipitor as the best-selling drug of all-time. View which stocks are hot on social media with MarketBeat's trending stocks report. AbbVie does not have the funds to pursue any large M&A deals, but it does not need to either, given the strength of its pipeline and products. The average ABBVIE INC stock forecast 2023 represents a 1.86% increase from the last price of $153.729995727539. AbbVie (ABBV) stock Forecast for 2021 - 2025 - PandaForecast.com Please disable your ad-blocker and refresh. All times are ET. This suggests a possible upside of 3.8% from the stock's current price. The next two approvals - for Navitoclax in Myelofibrosis and Teliso V in non squamous non-small cell lung cancer ("NSCLC") - are anticipated by management in 2024. Is AbbVie Stock A Buy Or A Sell With Humira Rivals Looming? When looking for ABBV stock forecasts, its important to bear in mind that analysts forecasts can be wrong. According to analysts' consensus price target of $161.12, AbbVie has a forecasted upside of 3.2% from its current price of $156.06. According to CompaniesMarketCap, the biopharmas market capitalisation stood at $272.38bn, making it the worlds 30th most valuable company. The company employs 50,000 workers across the globe. Both of these assets appear to be doing the job they were intended for - protecting AbbVie's dominance in various auto-immune markets - and now represent ~13% of AbbVie's total revenue generation. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. AbbVie's stock is owned by many different institutional and retail investors. What that means is, essentially it will be on formulary with biosimilars, but there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. (NYSE: ABBV) Abbvie's current Earnings Per Share (EPS) is $6.65. Research Reports & Trade Ideas - Yahoo Finance I am modelling for AbbVie to grow revenues at a compound annual growth rate of ~5% between now and 2030 with growth accelerating in the latter half of the decade. I have no business relationship with any company whose stock is mentioned in this article. As we can see, sales of Humira are still climbing, with losses in Europe - where revenues fell by 14% to $699m - offset by growth in the US, to $4.7bn, up 10% year-on-year. What is Richard A. Gonzalez's approval rating as AbbVie's CEO? American biopharmaceutical company Abbvie (ABBV) has surged nearly 13% year to date (YTD), and 35% year-over-year (YOY), as of 30 June. AbbVie Inc. (ABBV) Analyst Ratings, Estimates & Forecasts - Yahoo Finance Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents, Timothy J Richmond and Timothy J Richmond. It's hard to argue against Skyrizi and Rinvoq's performance to date, however, and with the total addressable market across all immunology indications likely well in excess of $100bn, I feel fairly comfortable that AbbVie can grow this division's revenues even as the world's biggest ever selling drug exits stage left. AbbVie's total revenue grew a solid 51% to $50.2 billion over the last twelve month period, compared to $33.0 billion in 2019. Based on earnings estimates, AbbVie will have a dividend payout ratio of 54.11% next year. What intrigues here is the possibility of RGX-314, an anti-VEGF gene therapy that Gonzalez believes "has the potential to be a one-time treatment for wet AMD, diabetic retinopathy and other chronic retinal conditions". Pessimistic target level: 151.42 Optimistic target level: 154.48 ABBV (ABBV) Monthly Stock Prediction for 2023 Full forecast for 2023 AbbVie forecast for this year As well as the stock price gains AbbVie has always paid a handsome dividend - which has increased by 270% since the Pharma's inception, currently paying $1.48 per quarter, for a current yield of 4% - the highest in the large Pharmaceutical sector. The companys original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. AbbVie probably does not want to be recognized as simply an immunology giant however, it wants to be substantially more diversified and like all major Pharma's it has a strong long-term focus on oncology. The company may not generate as much excitement as some of the other members of the "Big 8" - most notably Eli Lilly and its weight loss franchise, but the path to revenue growth, expanding margins and a growing share price is clear. Receive ABBV Stock News and Ratings via Email. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Negative dynamics for AbbVie shares will prevail with possible volatility of 1.976%. The companys full-year adjusted diluted EPS guidance excluded any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of the year, as both cannot be reliably forecasted. Bhd., AbbVie Sp. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. AbbVie could be the biggest global Pharma by revenue generation in 2028. Johnson & Johnson Stock Forecast 2023 - 2025 - 2030 As we look beyond 2025, we expect combined sales for Skyrizi and Rinvoq to exceed the peak revenues achieved by Humira, which was more than $21 billion. My No. Analysts have tipped the drug to achieve peak sales of $2.75bn, and although the emergence of CAR-T therapies and some concerns around safety - notably cases of cytokine release syndrome ("CRS') - persist, this revenue figure is achievable in my view. I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. The important point here is that physicians will not necessarily be under any pressure to switch patients from Humira to a biosimilar, given, as Gonzalez puts it: there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. Since then, however, the stock price has fallen 18% to its current price of $142.6. That is a significant difference because at a forward P/E of 10x AbbVie stock looks like a solid buy opportunity, but at a P/E of 20x, when we consider the risk/challenge of Humira's LOE, prospective investors may prefer to maintain a watching brief as opposed to opening a position. Neuroscience is one of AbbVie's most intriguing divisions and perhaps the hardest to model. Past performance is no guarantee of future results. The dividend payout ratio of AbbVie is 89.56%. We continue to anticipate a clearer path to strong sales growth in 2025 with high-single-digit compounded annual growth rate to the end of this decade. It pays a dividend yield of 3.83%, putting its dividend yield in the top 25% of dividend-paying stocks. All content of the Dow Jones branded indices S&P Dow Jones Indices LLC 2019 and/or its affiliates. Johnson & Johnson Free Cash Flow Forecast for 2023 - 2025 - 2030. The acquisition expanded AbbVies neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies. 1 dividend stock for a LIFETIME of income. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. The company issued revenue guidance of -. Abbvie Stock Forecast 2023 In the Biopharmaceutical Industry, Abbvie has been able to create a leadership position in the market in each business segment with different brand names in different business categories like Immunology, Hematologic Oncology, Neuroscience, Aesthetics, and Eye Care. Build a CFD portfolio with your favourite companies. . View the best growth stocks for 2023 here. AT&T Inc. (T) stock forecast and price target Find the latest AT&T Inc. T analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. All rights reserved. The review period was extended by three months in order for the FDA to review additional data submitted by AbbVie. Duodopa is approved for Parkinson's Disease but Gonzalez believes that the subcutaneous non-surgical delivery system of candidate ABBV951 can "significantly expand the patient population currently addressed by Duopa", and sees the drug as yet another future blockbuster. Forecasts shouldnt be used as a substitute for your own research. In the last two years, Aurora Cannabis's Revenue has fallen from C$245.54M to C$245.25M - a 0.12% decrease. And it couldnt be more wrong! If you rely on the information on this page then you do so entirely on your own risk. The company provided earnings per share (EPS) guidance of $10.70- for the period. ABBV Stock 12 Months Forecast. Although management reminded analysts that "Imbruvica continues to be the total market share leader across all lines of therapy in CLL", the outlook does not look especially promising. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. Retail sales were up but so was inflation which meant more volatility for stocks. AbbVie Stock: Still A Solid Buy After Modeling Sales To 2030 At their peak, according to a slide from AbbVie's presentation at the JPMorgan (JPM), these 2 drugs are expected to generate more revenues than Humira at its peak. Read the conference call transcript. The company is focused on research and has a number of collaborations and partnerships to that end. To date, the company had invested more than $50 billion into research through more than 250 partnerships. Projections are based on making fundamental and technical studies of the ABBV stock price performance. Free Stock Analysis Report: See The True Value of Any Stock, The Best Strategy For Your Small Trading Account. While some of the gains are due to investor perception that it is a strong company, some view ABBV as a defensive stock, with most of the other stocks in the sector also doing well. ET comments We expect proof-of-concept data from roughly a dozen additional early stage oncology opportunities over the next couple of years. If signs point to that happening I will likely be revising my target price upwards again, but I am playing it more conservative as nobody truly knows the scale of losses after the Humira LOE. These are mostly related to the US Food and Drug Administrations (FDA) approval of Abbvies drug Rinvoq for ulcerative colitis and positive top-line results from the Phase 3 induction study U-EXCEL. Management has previously stated that it expects total revenues to decline in 2023 following the Humira LOE, followed by a return to growth in 2024, and a "high single digit CAGR" maintained through the remainder of the decade. Stock Price Forecast The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. In terms of market cap, it ranks third behind Pfizer ( PFE) and Novo Nordisk ( NVO ). It is important to do your own research, and remember that your decision to trade depends on your attitude to risk, your expertise in the market, the spread of your investment portfolio and how comfortable you feel about losing money. I had felt this could be an issue for Skyrizi and Rinvoq, given it is rare for a drug to be as dominant as Humira was, but although the level of competition is fierce, both drugs are more than meeting expectations, and with the entire auto-immune market worth as much as $45 - $50bn, it does seem possible that Skyrizi and Rinvoq could one day generate >$20bn revenues between them, as management hopes. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Abbvie has a strong pipeline of projects ahead, and has recently received US FDA approval of its ulcerative colitis drug Rinvoq. Your current $100 investment may be up to $188.28 in 2028. Naturally, if there is a more effective and safe drug than Humira available for the same indication, then physicians are likely to prescribe it over Humira, or a Humira biosimilar. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Although the company has admitted that 2023 earnings will likely be down in 2022 - guidance for last year is for earnings per share ("EPS') of $13.84 - $13.88 on an adjusted diluted basis, versus $12.7 in 2021 - Gonzalez and his team were making some bold promises to investors at this year's JP Morgan Healthcare conference. I write about Biotech, Pharma and Healthcare stocks and share investment tips. AbbVie is a leading dividend payer. AbbVie Stock Forecast 2022 - 2025 - 2030 | StockForecast.com ABBV - AbbVie Stock Prediction 2025 - 2030 (my table and forecasts). Net earnings also saw a steep rise to $4.49bn from $3.55bn, while net revenue jumped to $13.54bn from 13.01bn. Forecast . Any company is likely to struggle if sales of its best-selling asset begin to decline by ~20% per annum, which is traditionally the rate at which patent expired drugs' sales slip, but when the drug in question accounts for >35% of a company's sales, as Humira does, the situation becomes even more serious. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions. AbbVie declared a quarterly dividend on Thursday, February 16th. When I began this post it was in my mind to give AbbVie stock a "Hold" rating owing to an underwhelming - on some levels - set of Q2'22 earnings, some concerns around high revenue generating products such as Imbruvica, Juvederm, and Restasis, the disappearance of the Women's Health division, the imminent LOE for Humira and the high levels of debt. In my modeling table above, I estimate Humira sales will decline by 25% between 2022 and 2023, to ~$16bn, although some of that lost revenue will be gobbled up by Skyrizi/Rinvoq. The firm's revenue for the quarter was up 1.6% compared to the same quarter last year. Finally I can present a target price for AbbVie stock in 2023 using DCF / EBITDA analysis. Neuroscience looks highly promising too, and aesthetics capable of driving some respectable growth driven by old stager Botox. Richard A. Gonzalez has an approval rating of 88% among the company's employees. Abbvie (ABBV) stock price prediction is 262.23586323343 USD. The Abbvie According to AbbVie CEO Rick Gonzalez, speaking on the Q2'22 earnings call, "Skyrizi's total prescription share of the U.S. biological market (in psoriasis) has increased to approximately 26%", and". One share of ABBV stock can currently be purchased for approximately $156.06. Whether these factors make ABBV a good investment for you or not will depend on your portfolio composition, investment goals and risk profile, among other factors. Should I buy or sell AbbVie stock right now? The average Abbvie stock price prediction forecasts a potential upside of 7.07% from the current ABBV share price of $155.27. High institutional ownership can be a signal of strong market trust in this company. AbbVie is led by CEO and Chairman Rick Gonzalez - likely the only Pharma CEO who lacks a college degree - who has successfully defended Humira from generic drug competition by adopting a controversial strategy of continually applying for new patents related to minor changes in manufacturing methods or administration, often referred to as a "patent thicket". I have plugged my revenue expectations into this table knowing that they closely match AbbVie management's own expectations based on what they have said in public. Zscaler, Inc Plummets, Is It Time To Buy The Dip? Shares are consolidating with a buy. 67.71% of the stock of AbbVie is held by institutions. My detailed modeling suggests there is 15-20% upside to look forward to in the short term and that ABBV stock remains a solid long-term buy opportunity for investors. AbbVie has a P/B Ratio of 15.97. The surge in revenues can primarily be attributed to its Allergan. The average price target represents a 6.33% change from the last price of $153.90. Without the additional patents - >130 in total - Humira would have lost its market exclusivity in 2016, but having eventually lost protection in Europe, which has resulted in a sales decline from $6.3bn in 2018, to ~$2.7bn in 2022, Humira will finally face generic competition in the US from the beginning of this year. Only you can design whether Abbvie stock is the right investment for you. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most.